Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan Plus Berzosertib in SCLC, EP-SCNC and HRD Cancers
NCT04826341Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2021
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, berzosertib in small cell lung cancer (SCLC), small cell neuroendocrine carcinoma (SCNC), cancer, solid tumor, sponsored by National Cancer Institute. Started Sep 2021; status: completed.
02
Drugs
sacituzumab govitecanberzosertib
03
Conditions
small cell lung cancer (SCLC)small cell neuroendocrine carcinoma (SCNC)cancersolid tumor
Beyond the preview
Go deeper on NCT04826341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826341.